article

1. Patient-Reported Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Are the Answers in Front of Our Noses?.  Arthritis care & research.  2024
2. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica..  Rheumatic diseases clinics of North America.  50:255-267. 2024
3. Current perspective on infections and mitigation strategies in primary systemic vasculitis..  Current rheumatology reports.  26:279-289. 2024
4. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica..  Annals of the rheumatic diseases.  83:48-57. 2024
5. Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group..  Annals of the rheumatic diseases.  2023
6. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide..  Arthritis care & research.  76:288-294. 2023
7. Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the ACR Rheumatology Informatics System for Effectiveness registry..  Arthritis care & research.  76:259-264. 2023
8. Association of patient copayment and medication adherence in systemic lupus erythematosus..  Lupus science & medicine.  10. 2023
9. Early referral of patients with suspected polymyalgia rheumatica - A systematic review..  Seminars in arthritis and rheumatism.  -. 2023
10. An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists..  Rheumatology (Oxford, England).  62:2797-2805. 2023
11. Erratum to "Social media for research discourse, dissemination, and collaboration in rheumatology"..  Rheumatology and immunology research.  4:107-108. 2023
12. Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries..  Lupus science & medicine.  10. 2023
13. Should race be considered in diagnosing giant cell arteritis? - Authors' reply..  The Lancet. Rheumatology.  5:e372-e373. 2023
14. Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status..  Rheumatology (Oxford, England).  62:1621-1626. 2023
15. Giant cell arteritis can occur in people of colour..  The Lancet. Rheumatology.  5:e175-e177. 2023
16. Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019..  Rheumatic diseases clinics of North America.  49:695-711. 2023
17. Navigating use of rituximab during the COVID-19 pandemic..  The Lancet. Rheumatology.  5:e63-e64. 2023
18. Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?.  Seminars in arthritis and rheumatism.  -. 2022
19. Supporting International Medical Graduates in Rheumatology: A Call to Action..  Arthritis & rheumatology (Hoboken, N.J.).  75:145-148. 2022
20. Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia..  Rheumatology (Oxford, England).  61:4455-4464. 2022
21. Keep It in Mind: Assessing the Risk of Dementia in Patients With Rheumatoid Arthritis and Opportunities for Intervention..  The Journal of rheumatology.  50:3-5. 2022
22. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey..  RMD open.  8. 2022
23. Omicron breakthrough infections in patients with immune-mediated inflammatory diseases..  The Lancet. Rheumatology.  4:e751-e752. 2022
24. Comparing cardiovascular risk of patients with rheumatoid arthritis within the Social Security Disability Insurance with those commercially insured..  Arthritis research & therapy.  24:-. 2022
25. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database..  Seminars in arthritis and rheumatism.  -. 2022
26. Where do we go after GiACTA?.  Rheumatology (Oxford, England).  61:2720-2721. 2022
27. Baseline Factors Associated with Self-reported Disease Flares Following COVID-19 Vaccination among Adults with Systemic Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey..  Rheumatology (Oxford, England).  61:SI143-SI150. 2022
28. Response to Letter to the Editor: Comment on the Review Article: "ANCA-Associated Vasculitis in Latin America. A systematic Literature Review: About Their Epidemiology and Their Clinical Features" by Victor R. Pimentel-Quiroz, et al. (J Clin Rheumatol 2022;28:44-51)..  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.  28:e682-e683. 2022
29. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis..  Arthritis & rheumatology (Hoboken, N.J.).  74:766-775. 2022
30. Clinical Features of ANCA-Associated Vasculitis in African American Patients in the United States: A Single-Center Medical Records Review Study..  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.  28:212-216. 2022
31. The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey..  Rheumatology advances in practice.  6:-. 2022
32. COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey..  The Lancet. Rheumatology.  4:e237-e240. 2022
33. Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset..  ACR open rheumatology.  4:300-305. 2022
34. ANCA-Associated Vasculitis in Latin America: A Systematic Literature Review: About Their Epidemiology and Their Clinical Features..  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.  28:44-51. 2022
35. Dr. Conway et al reply..  The Journal of rheumatology.  49:120-121. 2022
36. Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees..  ACR open rheumatology.  4:128-133. 2021
37. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study..  The Lancet. Rheumatology.  3:e855-e864. 2021
38. Dr. Conway et al reply..  The Journal of rheumatology.  2021
39. COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance..  The Journal of rheumatology.  49:110-114. 2021
40. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey..  RMD open.  7. 2021
41. The role of immunomodulatory medications in the treatment of COVID-19..  Current opinion in rheumatology.  33:431-445. 2021
42. Reply..  Arthritis & rheumatology (Hoboken, N.J.).  73:1767-1768. 2021
43. The COVID-19 Pandemic and Rheumatology: Impact on Providing Care in Latin America and Around the World..  The Journal of rheumatology.  48:1501-1503. 2021
44. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases..  The Lancet. Rheumatology.  3:e707-e714. 2021
45. Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set..  Seminars in arthritis and rheumatism.  51:1139-1145. 2021
46. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial..  Arthritis & rheumatology (Hoboken, N.J.).  73:1514-1522. 2021
47. Comment on: Handgrip strength is a comorbidity marker in systemic necrotizing vasculitides and predicts the risk of fracture and serious adverse events..  Rheumatology (Oxford, England).  60:e184-e185. 2021
48. Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis..  Seminars in arthritis and rheumatism.  51:292-298. 2021
49. Reply to 'Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science'..  Expert review of clinical immunology.  17:105-107. 2020
50. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective..  The Lancet. Rheumatology.  3:e71-e82. 2020
51. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis..  Arthritis & rheumatology (Hoboken, N.J.).  73:36-47. 2020
52. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series..  Arthritis & rheumatology (Hoboken, N.J.).  72:1990-1997. 2020
53. Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review..  The Journal of rheumatology.  48:1053-1059. 2020
54. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19..  Expert review of clinical immunology.  16:659-666. 2020
55. Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis..  Seminars in arthritis and rheumatism.  50:988-995. 2020
56. Localized Granulomatous with Polyangiitis (GPA): Varied Clinical Presentations and Update on Treatment..  Current allergy and asthma reports.  20:-. 2020
57. Festina lente.  Annals of the rheumatic diseases.  79:734-736. 2020
58. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19..  Annals of internal medicine.  172:819-821. 2020
59. Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide?.  Rheumatic diseases clinics of North America.  45:379-398. 2019
60. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale..  Contemporary clinical trials.  238-44. 2016
61. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications..  Therapeutic advances in musculoskeletal disease.  8:145-59. 2016
62. A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study..  Contemporary clinical trials communications.  32-38. 2016
63. Fracture mortality: associations with epidemiology and osteoporosis treatment..  Nature reviews. Endocrinology.  10:592-602. 2014
64. Comorbidities in patients with crystal diseases and hyperuricemia..  Rheumatic diseases clinics of North America.  40:251-78. 2014
65. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis..  Clinical therapeutics.  35:1850-61.e1. 2013
66. Cryopreservation modulates the detection of regulatory T cell markers..  Cytometry. Part B, Clinical cytometry.  82:54-8. 2011